Spots Global Cancer Trial Database for A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Official Title: A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females
Study ID: NCT03900572
Conditions
Study Description
Brief Summary: A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.
Detailed Description:
Eligibility
Minimum Age: 9 Years
Eligible Ages: CHILD, ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Locations
Sichuan Provincial Center for Disease Prevention and Control, Chengdu, Sichuan, China
Contact Details
Name: Xuecheng LIU, BS
Affiliation: Sichuan Provincial Center for Disease Prevention and Control
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
